RFP for Radiopharmaceutical Providers

MD Anderson Cancer Center is seeking qualified suppliers to provide a full portfolio of radiopharmaceutical products—including isotopes, diagnostic agents, contrast media, and combination agents—for clinical use across its main campus and satellite facilities. The supplier must have a proven track record in the Houston market, be able to meet ongoing and future product needs, and comply with extensive quality, safety, and regulatory requirements (NRC, FDA, DOT, USP, cGMP). The contract will be awarded on a best‑value basis and will require a HUB Subcontracting Plan and compliance with Texas ethics and disclosure statutes. • Supply and deliver isotopes, diagnostic radiopharmaceuticals, contrast media, and combination agents for clinical use. • Provide 24/7 delivery capability, staging, inventory management, online order‑tracking, and robust shortage‑mitigation processes. • Meet stringent quality‑assurance, QA/QC, ISO, and regulatory compliance (NRC, FDA, DOT, USP) and submit required HUB Subcontracting Plan. • Participate in a pre‑proposal Zoom meeting on April 17 2026 (highly recommended) and respond to the RFP by May 5 2026. • Contract governed by MD Anderson’s Standard Terms and Conditions; award will be based on best‑value evaluation.